Gilead Sciences Inc. has announced transformative data in the field of oncology, set to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Annual Congress. The data includes late-breaking results from the Phase 3 ASCENT-04 study, which demonstrated a significant improvement in progression-free survival for patients receiving Trodelvy® plus Keytruda® compared to Keytruda and standard chemotherapy in treating PD-L1 positive metastatic triple-negative breast cancer. Additionally, novel investigational CAR T-cell therapies will be showcased, including a promising dual-target approach for recurrent glioblastoma and updated findings for anitocabtagene-autoleucel in relapsed/refractory multiple myeloma. These findings underscore Gilead's commitment to advancing next-generation therapies and transformative cancer treatments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.